Does LENZ Therapeutics, Inc. (LENZ) have what it takes to be a top stock pick for momentum investors? Let's find out.

Shares of LENZ Therapeutics, Inc. (LENZ) have gained 17% over the past four weeks to close the last trading session at $33.73, but there could still be a solid upside left in the stock if short ...

In other recent news, Lenz Therapeutics announced an exclusive licensing agreement with Laboratoires Théa for the commercialization of its presbyopia treatment, LNZ100, in Canada.

Learn about the executive team and board of directors at LENZ Therapeutics Inc (LENZ:XNAS) and review their bios and compensation over the latest fiscal years.

Discover the "Catalyst Monitor Q3 2025" report, offering insights from KOLs on 18 significant catalysts, including FDA approvals for Ascendis Pharma, PTC Therapeutics, Lenz Therapeutics, and more. It ...

Find the latest information on LENZ Therapeutics, Inc. Common Stock (LENZ) insider activity and insider shares traded to make sound investments with Nasdaq.com.

In other recent news, Lenz Therapeutics announced an exclusive licensing agreement with Laboratoires Théa for the commercialization of its presbyopia treatment, LNZ100, in Canada. The deal could bring ...

Dan Lenz iHeartMedia has named Dan Lenz its market president for Milwaukee. He’ll be responsible for all of the cluster’s operations, ranging from sales to programming. For Lenz, the move is a ...

Dan Lenz, previously SVP of Sales, is now Market President for iHeartMedia Milwaukee, overseeing programming and sales across the cluster.